OncoMatch/Clinical Trials/NCT06157151
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Is NCT06157151 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies PRGN-2009 plus Pembrolizumab for cervical cancer.
Treatment: PRGN-2009 plus Pembrolizumab — This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Cervical Cancer
Biomarker criteria
Required: HPV positive
Disease stage
Required: Stage IV
Metastatic disease required
Measurable disease that can be accurately measured by RECIST v1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy (pembrolizumab)
Must have been treated with pembrolizumab, either as monotherapy or in combination, for at least 6 weeks.
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Must have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- National Institute of Health · Bethesda, Maryland
- University of Washington · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06157151 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anti-PD-1 therapy.
Does this trial require HPV?
Yes, HPV positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages